Literature DB >> 19606922

A psychometric investigation of the Suicide Status Form II with a psychiatric inpatient sample.

Amy K Conrad1, Aaron M Jacoby, David A Jobes, Timothy W Lineberry, Catherine E Shea, Theresa D Arnold Ewing, Phyllis J Schmid, Susan M Ellenbecker, Joy L Lee, Kathryn Fritsche, Jennifer A Grenell, Jessica M Gehin, Simon Kung.   

Abstract

We investigated the psychometric validity and reliability of the Suicide Status Form-II (SSF-II) developed by Jobes, Jacoby, Cimbolic, and Hustead (1997). Participants were 149 psychiatric inpatients (108 suicidal; 41 nonsuicidal) at the Mayo Clinic. Each participant completed assessment measures within 24 hours of admission and 48-72 hours later. Factor analyses of the SSF core assessment produced a robust two-factor solution reflecting chronic and acute response styles. The SSF core assessment had good to excellent convergent and criterion validity; pre-post SSF ratings also demonstrated moderate test-retest reliability. The results replicated previous research and show that the SSF-II is psychometrically sound with a high-risk suicidal inpatient sample.

Entities:  

Mesh:

Year:  2009        PMID: 19606922     DOI: 10.1521/suli.2009.39.3.307

Source DB:  PubMed          Journal:  Suicide Life Threat Behav        ISSN: 0363-0234


  17 in total

Review 1.  Suicide as a derangement of the self-sacrificial aspect of eusociality.

Authors:  Thomas E Joiner; Melanie A Hom; Christopher R Hagan; Caroline Silva
Journal:  Psychol Rev       Date:  2015-11-02       Impact factor: 8.934

2.  "Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?"

Authors:  Laili Soleimani; Alison Welch; James W Murrough
Journal:  Curr Treat Options Psychiatry       Date:  2015-10-16

3.  Collaborative assessment and management of suicidality in an inpatient setting: results of a pilot study.

Authors:  Thomas E Ellis; Kelly L Green; Jon G Allen; David A Jobes; Michael R Nadorff
Journal:  Psychotherapy (Chic)       Date:  2012-03

4.  How does active substance use at psychiatric admission impact suicide risk and hospital length-of-stay?

Authors:  Keith A Miller; Mario J Hitschfeld; Timothy W Lineberry; Brian A Palmer
Journal:  J Addict Dis       Date:  2016-04-18

Review 5.  Anxiety and its disorders as risk factors for suicidal thoughts and behaviors: A meta-analytic review.

Authors:  Kate H Bentley; Joseph C Franklin; Jessica D Ribeiro; Evan M Kleiman; Kathryn R Fox; Matthew K Nock
Journal:  Clin Psychol Rev       Date:  2015-12-02

6.  Use of the Suicide Status Form-II to investigate correlates of suicide risk factors in psychiatrically hospitalized children and adolescents.

Authors:  Magdalena Romanowicz; Stephen S O'Connor; Kathryn M Schak; Cosima C Swintak; Timothy W Lineberry
Journal:  J Affect Disord       Date:  2013-07-13       Impact factor: 4.839

Review 7.  The assessment and management of suicide risk: state of workshop education.

Authors:  Anthony R Pisani; Wendi F Cross; Madelyn S Gould
Journal:  Suicide Life Threat Behav       Date:  2011-04-07

Review 8.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

9.  A Randomized Controlled Trial of the Collaborative Assessment and Management of Suicidality (CAMS) Versus Treatment as Usual (TAU) for Suicidal College Students.

Authors:  Jacqueline Pistorello; David A Jobes; Robert Gallop; Scott N Compton; Nadia Samad Locey; Josephine S Au; Samantha K Noose; Joseph C Walloch; Jacquelyn Johnson; Maria Young; Yani Dickens; Patricia Chatham; Tami Jeffcoat
Journal:  Arch Suicide Res       Date:  2020-04-10

10.  Rapid Adoption and Implementation of Telehealth Group Psychotherapy During COVID 19: Practical Strategies and Recommendations.

Authors:  Ajeng J Puspitasari; Dagoberto Heredia; Melanie Gentry; Craig Sawchuk; Bernie Theobald; Wendy Moore; Michael Tiede; Christine Galardy; Kathryn Schak; Mayo Clinic
Journal:  Cogn Behav Pract       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.